

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Comparative bioequivalence study of the Omeprazole 10-mg Sachet manufactured by Nafas Zist Pharmed Pharmaceutical Company

Protocol summary

Study aim

Examining the equivalency of domestically produced tablet formulations with brand samples

Design

Cross-over unblinded randomization

Settings and conduct

The number of 24 healthy volunteers in the age range of 18-60 years and the weight range of $18 < \text{BMI} < 30$, male, who are randomly and voluntarily selected through public notification. 1 tablet is taken fasting and blood is taken at 15 time points. A week later, the process is repeated for the external medicine

Participants/Inclusion and exclusion criteria

The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (γ -GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form

Intervention groups

After taking a pill for internal production, 3 milliliters of blood will be collected from the volunteer in 15 time intervals for 12 hours. A week later, the process is repeated for a brand sample pill. The drug concentration is measured in plasma

Main outcome variables

Studying the Drug pharmacokinetic parameters

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20130313012810N9**

Registration date: **2023-05-08, 1402/02/18**

Registration timing: **retrospective**

Last update: **2023-05-08, 1402/02/18**

Update count: **0**

Registration date

2023-05-08, 1402/02/18

Registrant information

Name

Hamed Hamishehkar

Name of organization / entity

Drug Applied Research Center, Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1336 3311

Email address

hamishehkar.hamed@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-04-15, 1402/01/26

Expected recruitment end date

2023-04-25, 1402/02/05

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative bioequivalence study of the Omeprazole 10-mg Sachet manufactured by Nafas Zist Pharmed

Pharmaceutical Company		Ethics committees	
Public title	Comparative bioequivalence study of the Omeprazole 10-mg Sachet manufactured by Nafas Zist Pharmed Pharmaceutical Company	1	
Purpose	Other	Ethics committee	
Inclusion/Exclusion criteria		Name of ethics committee	Ethics committee of Tabriz University of Medical Sciences
Inclusion criteria:	The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (γ-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw	Street address	Daneshghah St. Drug Applied Research Center
Exclusion criteria:	History of allergic or adverse reaction to Esomeprazole or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s) Patients with neutrophil count less than 500 cells/mm ³ Patients with lymphocyte count less than 500 cells/mm ³ Patients with serious infection (e.g., sepsis) or active infection, including local infection	City	Tabriz
Age	From 18 years old to 60 years old	Province	East Azarbaijan
Gender	Male	Postal code	5165665811
Phase	Bioequivalence	Approval date	2023-04-17, 1402/01/28
Groups that have been masked	No information	Ethics committee reference number	IR.TBZMED.REC.1402.088
Sample size	Target sample size: 24	Health conditions studied	
Randomization (investigator's opinion)	N/A	1	
Randomization description		Description of health condition studied	-
Blinding (investigator's opinion)	Not blinded	ICD-10 code	
Blinding description		ICD-10 code description	
Placebo	Not used	Primary outcomes	
Assignment	Crossover	1	
Other design features		Description	Plasma concentration of the drug
		Timepoint	15 sampling time till 12 h
		Method of measurement	Liquid Chromatography with tandem mass spectrometry (LC-MS-MS)
Secondary Ids	empty	Secondary outcomes	
		empty	
		Intervention groups	
		1	
		Description	Intervention group: Intervention group: Intervention group: This study examines the bioequivalence of Esomeprazole tablets produced by a domestic company with a foreign brand sample. We have only one intervention group and there is no control group. The intervention group, which includes healthy, fasting male volunteers, will receive a single dose, a 100 mg tablet manufactured by the pharmaceutical company Nafas Zist Pharmed and AstraZeneca brand, in two 12-hour periods with an interval of one week, on the day of the study. And in 15 different time periods up to 12 hours after

taking the medicine, blood samples will be taken from the volunteers in the amount of 3 ml each time, that is, a total of 45 ml within 12 hours. The training that will be given to the volunteers includes avoiding the consumption of drinks containing alcohol and xanthine and other interfering drugs in the prescription drug from 48 hours before the start of the study until the end of the study.

Category

N/A

Recruitment centers

1

Recruitment center

Name of recruitment center

Drug Applied Research Center, Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Nafas Zist Pharmed Pharmaceutical Company

Full name of responsible person

Mehdi Rouhi Razlighi

Street address

No. 6, Unit 5, Sattar Khan, Shadi Alley, Tehran

City

Tehran

Province

Tehran

Postal code

1441675816

Phone

+98 21 9200 1520

Email

info@nafaspharmed.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Nafas Zist Pharmed

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3181

Fax

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Web page address

http://darc.tbzmed.ac.ir/

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences

City

Tabriz
Province
East Azarbaijan
Postal code
51656-65811
Phone
+98 41 3336 3181
Fax
+98 41 3336 3311
Email
hamishehkar.hamed@gmail.com
Web page address
<http://darc.tbzmed.ac.ir/>

Person responsible for updating data

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Drug Applied Research Center, Tabriz University of
Medical Sciences
City

Tabriz
Province
East Azarbaijan
Postal code
51656-65811
Phone
+98 41 3336 3181
Fax
+98 41 3336 3311
Email
hamishehkar.hamed@gmail.com
Web page address
<http://darc.tbzmed.ac.ir/>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available